Defining patterns of care in the management of patients with brain metastases in a large oncology centre: A single‐centre retrospective audit of 236 cases by Bentley, Rebecca et al.
1 
 
Defining patterns of care in the management of patients with brain 
metastases in a large Oncology centre: A single-centre 
retrospective audit of 236 cases. 
Abstract 
Aims: The role of selected treatments for brain metastases (BM) is well documented; 
however the prevalence of these is not. We report on the patterns of care in the 
management of BM in a large Oncology centre.  
Materials and methods: We retrospectively audited 236 cases of newly diagnosed BM from 
January 2016 to December 2017 by looking at 2 years of radiology reports and gathered 
data on primary site, survival, treatment received, palliative care input and brain metastases 
related admissions.  
Results Eighty-two percent of cases were related to lung, breast and melanoma primaries. 
Half of patients received a form of treatment with the other half receiving best supportive 
care. Of these, whole brain radiotherapy (39%) and stereotactic radiosurgery (40%) were the 
most common treatment modalities. Most common reasons for admissions were headaches, 
seizures, weakness and confusion.  
Conclusion: This is the first study in the UK that gives an in-depth overview of the real world 
management of brain metastases. We have demonstrated the prevalence of treatment 
across the spectrum of brain metastases patients. Radiotherapy is the mainstay of treatment 
in nearly 80% of cases; however care needs to be taken in ensuring that SRS is offered to 
those who are suitable. 
Introduction  
Brain metastases occur in 20-40% of patients with metastatic cancer (Nathoo, 
Chahlavi, Barnett, & Toms, 2005). The last decade has seen significant advances in 
systematic anti-cancer treatment (SACT) and patients are living longer than ever before. 
Despite these advances, brain metastases represent a unique challenge as many SACTs do 
not reliably cross the blood-brain barrier. Historically, patients were managed with whole 
brain radiotherapy (WBRT) with a role for neurosurgery in selected cases (Mehta et al., 
2010). The results of the QUARTZ trial has led to WBRT falling out of favour in the UK for 
lung cancer patients (Mulvenna et al., 2016) and it’s known neurocognitive toxicity has led to 
concerted efforts to manage brain metastases differently, either with hippocampal sparing 
WBRT or with stereotactic radiosurgery (SRS) (Gondi et al., 2014; Pinkham, Sanghera, Wall, 
Dawson, & Whitfield, 2015).  
SRS is as effective as surgery at achieving good local control and is proven to 
increase overall survival in selected patients (Linskey et al., 2010). Until recently, access to 
SRS in the UK was limited to only a few sites. In 2016, NHS England commissioned a 
number of new SRS services meaning that SRS is now more accessible to more patients 
closer to home (“NHS England » Patients benefiting from advanced brain tumour treatment 
set to double,” n.d.). The wain of WBRT and the widespread availability of SRS has created 
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a paradigm shift in the way we manage brain metastases. NHS England mandates that 
patients suitable for SRS should be discussed at a specialist MDT comprising a 
Neurosurgeon, a Neuroradiologist and a Clinical Oncologist who specialises in SRS (NHS 
Commissioning Board Clinical Reference Group for Stereotactic Radiosurgery. Clinical 
Commissioning Policy: Stereotactic Radiosurgery/Radiotherapy for Cerebral Metastases. 
(Reference: NHSCB/D05/P/d NHS Commissioning Board), 2013). 
Many patients with brain metastases are likely to be unsuitable for aggressive 
management, however early contact with palliative care has been shown to improve quality 
of life and potentially survival (Greer et al., 2012; Hearn & Higginson, 1998; Temel et al., 
2010). The role of each treatment modality for brain metastases is well defined but there is 
no up-to-date information on the frequency of their use in modern UK practice. The aims of 
this audit were to better understand current practice by identifying: 1) The treatments 
undertaken for brain metastases across tumour types; 2) If all patients undergoing SRS are 
discussed at a specialist regional MDT meeting prior to treatment; 3) If, based on imaging 
and available documentation, whether patients are potentially missing the opportunity to be 
offered SRS. 
Material and Methods  
Over a two year period (1st January 2016 – 31st December 2017), adult patients with 
a new radiologically confirmed diagnosis of brain metastases were identified by retrieving all 
Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) head scans that 
contained the words ‘metastases’, ‘metastasis’ or ‘met’ in the scan’s contemporaneous 
report. Only patients with a confirmed primary cancer were included. Primary intracranial 
tumours and skull vault metastases were excluded, as were patients attending from outside 
our trust’s local catchment area, the latter to best reflect the incidence of treatments such as 
surgery and SRS in a typical cancer centre as our trust is a regional referral centre for 
Neurosurgery and SRS. 
Information recorded included patient demographics, primary cancer site, status of 
extracranial disease, date of diagnosis of brain metastases, involvement of the Neuro-
Oncology multidisciplinary team (MDT), treatment recommended, treatment received, 
number, duration and reasons for hospital admissions and survival (as of the 29th of April 
2018). 
Patients who underwent SRS, WBRT or surgery were considered to have received a 
local therapy for their brain metastases. Patients receiving systemic therapy without local 
therapy are considered as a separate treated group and are identified as ‘SACT’ below. 
Patients who did not receive either local or systemic therapy for their brain metastases were 
identified as best supportive care (BSC). 
In the time period of the audit the regional Neuro-Oncology Multi-Disciplinary Team 
meeting (MDT) was the forum for discussion of all patients considered for SRS or surgical 
management of brain metastases (amongst other conditions). 
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Results 
Demographics 
Out of 2,422 scans, reviewed, there were 236 cases of newly diagnosed brain 
metastases in the predefined review period. The median age at diagnosis was 65 years 
(range 30-87). The median survival across all groups was 115 days (range 1-829). There 
were more females (58%) than males (42%), a difference mainly attributable to the number 
breast cancers patients with brain metastases (20%). Patient characteristics and 
demographics are summarised in Table 1.  
Lung cancer represented the most common primary site (49%), followed by breast 
(20%) and melanoma (13%). At the time of diagnosis, just under half of all patients (47%) 
had controlled extracranial disease. Median survival varied by primary site with breast 
carrying the best prognosis (202 days) and lung carrying the worst (95 days). Survival based 
on primary site is shown in Figure 1. Tumour specific demographics are summarised in 
Table 3.  
Treatments and Therapies 
Half of the cases received some form of local therapy for their brain metastases with 
11% receiving systemic therapy and 39% receiving best supportive care. There were 127 
local therapies delivered to 118 patients. Of these and SRS (40%) WBRT (39%) were the 
most common with surgery (21%) the least common intervention. Some patients had more 
than one local therapy. Local therapy modality varied according to primary tumour site. In 
breast, WBRT (54%) was the most common treatment followed by SRS (15%). In lung and 
melanoma, this was reversed with SRS (21% & 53% respectively) more commonly used 
than WBRT (14% & 6% respectively). Patients who received SRS lived the longest; their 
median survival was not yet reached at assessment, compared to surgery (210 days) and 
WBRT (202 days). Patients receiving SACT (without any local therapy) had a median 
survival of 149 days. Treatment and therapy related outcomes are summarised in table 2.  
Survival based on treatment modality is shown in Figure 2. 
Of the 39% of patients who did not receive any treatment; median survival was 42 
days. Of these, 39% had contact with palliative care services. Amongst patients treated with 
local therapy, 54% were seen by palliative care. Of the patients treated with systemic 
therapy alone, 19% had contact with palliative services. Contact rates to palliative services 
by primary site are summarised in Table 4. 
MDT Referrals 
Overall 53% of patients were discussed at the regional Neuro-Oncology MDT. There 
was an increase of 6% in referrals from 2016 to 2017, however this varied according to 
primary site with 63% of melanoma cases, 53% of lung cases, 64% of other cases and 35% 
of breast cases discussed. Year on year, melanoma and lung referrals increased (by 51% & 
9% respectively) whilst other referrals remained static, however breast referrals dropped by 
7%. All patients who had surgery, 87% of patients who had SRS and 63% of patients who 
received WBRT were discussed. Of the 27 patients (37%) who had WBRT without MDT 
discussion 21 of those (75%) had a breast primary. Ten of the 26 (38%) patients continuing 
4 
 
or commencing systemic therapies were discussed. Two percent of patients managed with 
BSC alone were discussed. MDT referral rates are shown in Table 3.   
Admissions  
Sixty-nine percent of patients had a brain metastases related admission. There were 
305 admissions accounting for 2318 bed days. The first diagnosis of brain metastases 
occurred as a direct result of an admission in 63 patients (27%). The median length of stay 
was 7 days. The most common reasons for admission were seizures (18%) headaches, 
(17%) confusion (16%) and weakness (14%). Patients with lung primaries had the longest 
median stay (12 days) and the largest number of admissions (50% of all admissions) 
Bed days varied depending on the treatment received. Patients who received SRS 
had the fewest bed days as a proportion of total follow up days. They had 63 admissions and 
491 bed days, which represented 3% of the total follow up days. Admissions based on 
treatment are summarised in Table 2, whilst admissions based in primary site are shown in 
Table 3. 
Cases where SRS could have been given 
 All cases which received WBRT were reviewed to see if there was potential to offer 
SRS at the time that their WBRT was given. To be considered as a missed opportunity, the 
case must have had radiologically suitable disease as recommended by contemporary local 
guidelines (volume <20cc and <10 lesions) and the clinical information available must 
indicate that the patient might be suitable (i.e. prognosis >6 months, KPS >/=70, controllable 
ECD). If a case was discussed at MDT prior to WBRT then these were discounted. Based on 
these criteria we identified seven cases where a patient had WBRT and would have been 
suitable for SRS. All seven patients had breast primaries.  
Discussion  
This audit represents a comprehensive, up to date picture of brain metastases 
management and outcomes in a large oncology centre; the 4th largest acute trust in the UK. 
Though our centre is a tertiary referral centre for the region and encompasses a population 
of 4.5 million in its regional neurosurgical and SRS service, we have purposefully limited the 
scope of our audit to the secondary care catchment population of about 1 million. This was 
done to avoid artificially inflating the incidence of brain metastases and to avoid skewing the 
patterns of treatment in favour of surgery and SRS. A recent analysis of the trusts catchment 
population determined that it was generally representative of the UK average when broad 
sociological, demographic and health and wellbeing characteristics of the population are 
compared to national figures(McCormick et al., 2017). The frequency and demographics of 
the primary malignancies represented here is broadly similar to other cohort studies 
(Berghoff et al., 2016). 
There are no accurate figures reporting incidence of brain metastases in the UK or 
indeed internationally. In the USA best estimates suggest that there would be 70,000 new 
cases per year- giving a crude incidence of 23/100,000 (Landis, Murray, Bolden, & Wingo, 
1998). In our data, 236 patients were diagnosed in a 2 year period. Using the catchment 
population figure of 1 million this would mean a crude incidence of 12/100,000 per year.  
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 Over the last decade there have been rapid advances in the systemic management 
of many cancers including melanoma, breast cancer and lung cancer. These primary sites 
represented the majority of cases of brain metastases in our case series. In spite of these 
advances, many SACT drugs do not reliably induce a response in the brain thus creating a 
need to separately manage brain metastases in some cases (Mehta et al., 2010). It should 
be noted; such is the rate at which evidence is changing, that a recent single–group phase 2, 
trial in melanoma patients found that combination immunotherapy had a 57% response rate 
in unirradiated brain metastases (Tawbi et al., 2018). Within lung cancer, there is also 
significant interest in targeted drug therapies in the management brain metastases however 
current recommendations are that local therapy (SRS or neurosurgery) should be 
considered as standard of care (Preusser et al., 2018). 
For many, brain metastases still represent a poor prognosis (Sperduto et al., 2010). 
Our figures show that nearly forty percent of the patients newly diagnosed were suitable for 
best supportive care only. Median survival in this group was short (42 days). The QUARTZ 
trial, in lung cancer, showed that WBRT impairs quality of life without improving survival 
(Mulvenna et al., 2016). The median survival in that trial was similar to our best supportive 
care group therefore we feel that the avoidance of WBRT in this poor prognostic group was 
correct and would likely only have caused deterioration in quality of life.  
In our study, radiotherapy (both SRS & WBRT) accounted for nearly 80% of the local 
treatments. WBRT was used in over a fifth of all patients. WBRT is associated with 
significant neurocognitive impairment as well as alopecia (Pinkham et al., 2015). Using an 
IMRT solution to keep hippocampal doses below 9Gy, neurocognitive impairment can be 
reduced from 30% to less than 10%, however this is not in routine use in our centre (Gondi 
et al., 2014). Despite this, WBRT still plays an important role in those who are not suitable 
for other, more aggressive, therapies. Using lung cancer as an example, only 6 NSCLC lung 
cancer patients received WBRT which follows the outcome of the QUARTZ trial. Of these, 3 
had an EGFR mutation and the other 3 had controlled extracranial disease, with 4 of the 6 
living for at least 6 months. This suggests that physicians are using WBRT pragmatically in 
those cases where a reasonable prognosis is expected rather than blanket use of WBRT. 
Of the 36 breast patients who were treated, 26 received WBRT. Only one patient 
who received WBRT was later treated with SRS. During our review of the WBRT cases we 
identified 7 who could potentially have been offered SRS instead. This took into account 
contemporaneous local guidelines regarding suitability for SRS including performance 
status, radiological appearance and available documentation of clinical information to infer 
prognosis. Only cases which were not discussed at the neuro-oncology MDT prior to WBRT 
were considered. All of these cases were breast primaries. 
NHS England recommends that cases considered for SRS need to be discussed at a 
meeting with a Neurosurgeon, Neuroradiologist and a Neuro-oncologist present (NHS 
Commissioning Board Clinical Reference Group for Stereotactic Radiosurgery. Clinical 
Commissioning Policy: Stereotactic Radiosurgery/Radiotherapy for Cerebral Metastases. 
(Reference: NHSCB/D05/P/d NHS Commissioning Board), 2013). With the evolving role 
SRS plays in brain metastases management it is challenging for physicians to be up to date 
with rapidly evolving indications. One way to ensure patients are offered an expert opinion 
on brain metastases management would be to discuss all cases at a specialist MDT. In our 
study those specialities with highest referral rate to a specialist MDT had the highest rates of 
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SRS treatment. In lung and melanoma specialist advice was sought in 53% and 61% of 
cases respectively and, where treatment was recommended, SRS was offered in over 80% 
of cases. Conversely, only 35% of breast cases were discussed and the SRS rate was only 
19% in treated cases. This could have been doubled to 39% if all breast cases were 
discussed. Despite NHS guidance that all cases offered SRS are discussed at an 
appropriate MDT we found that this was the case in only 86% of cases. 
In total, a little over half of all cases were referred for a specialist MDT opinion. There 
is therefore already a culture of referring brain metastases cases for advice and this is most 
prevalent in the least common tumour sites with two-thirds of ‘other’ primaries seeking 
advice. In our regional Neuro-oncology MDT in 2017 brain metastases represented 17% of 
all cases discussed, an average of 9 per week. This two hour MDT discussed an average of 
52 cases and presuming the MDT runs to time left 2 minutes and 18 seconds per case.  
In the period from January 1st 2016 to April 29th 2018, our 236 patients had a 
cumulative follow-up of 42,221 days. Of these, 166 (70%) were admitted 305 times for a total 
of 2318 bed days. This represents about one day of hospitalisation for every 20 days of 
follow up. The best supportive care group spent the highest proportion of time in hospital 
(11.8%) followed by surgery (6.4%), SACT (5.8%), WBRT (5.3%) and compared to just 3% 
for the SRS group. There were 189 elective bed days associated with surgery which 
accounts for much of the excess over the SRS group and removing these reduces the 
unplanned bed days to 3.7% of total follow-up days. The estimated cost of the bed day 
varies from £306 for an excess stay bed day to £1609 for an emergency admission.(“Health 
and social care integration,” n.d.) Based on these figures the cost range for admissions is 
between £709,308 at the low end and £3,729,662 at the top. Whilst the true figure will lie 
between the two, elective admissions in our review were limited only to elective surgical 
admissions with the remainder relating to unplanned emergency admissions. In France, A 
recent analysis of the cost of brain metastases in non-small cell lung cancer demonstrated 
that the cost to health services of managing these patients was €533 per patient per month 
more than managing those with metastases elsewhere- a 22% difference (Girard et al., 
2018). 
Irrespective of primary site the four most common reasons for admission were 
seizure, confusion, weakness and headaches. Knowing this, it may be possible to better 
educate patients on the symptoms and, with proper support, avoid admission. For instance 
52 admissions (17%) were related to headaches: patient education with telephone support 
from a dedicated nurse specialist may help avoid many of these admissions. Similarly, 
seizures account for 56 admissions (18%) but this may be reduced with patient and carer 
education on seizure management with buccal midazolam and telephone support. A study of 
Health professionals’ perspectives in patients with brain tumours found that increased care 
co-ordination and improved communication is needed to improve the information needs of 
this group (Langbecker, Janda, & Yates, 2013). 
Though a high proportion of patients are nominally being managed with best 
supportive care, there is at present, no pathway for such patients to follow. Most of the 
contact with the palliative care team as inpatients following an emergency admission in what 
can be seen as a reactive approach to providing support. It is not clear why the referrals to 
palliative care services, especially amongst the supportive care group, are so low though it 
has been shown that the term ‘palliative care’ rather than ‘supportive care’ can make it less 
7 
 
likely for oncologists to refer patients for fear of causing distress (Fadul et al., 2009). Best 
supportive care, implemented properly and early, in combination with other treatments can 
lengthen life and provide a better quality of life (Temel et al., 2010). It should be noted that 
the patients with lung cancer have the highest contact with palliative care services; this 
coincides with implementation of an enhanced supportive care program for these patients 
set up in 2016. We anticipate that by implementing an enhanced supportive care pathway for 
patients with brain metastases we can encourage the early referral of these patients to 
proactive outpatient based palliative care services. 
Limitations 
Though practical, our search strategy of using imaging as a surrogate may have 
missed patients who had imaging in other centres and then returned for follow-up care in our 
centre. It is also possible that our search missed some cases of brain metastases in the first 
place. The incidence we report is therefore likely an underestimation. The retrospective 
nature of the audit relies on accurate documentation to infer possible treatment options. 
Though none were identified, there may have been valid reasons why WBRT was chosen 
over SRS in the patients who potentially missed out. 
Conclusion 
 This is the first study in the UK that gives an in-depth overview of the real world 
management of brain metastases. We have demonstrated the prevalence of treatment 
across the spectrum of brain metastases patients. Radiotherapy is the mainstay of treatment 
in nearly 80% of cases; however care needs to be taken in ensuring that SRS is offered to 
those who are suitable. Patients with brain metastases represent a complex and varied 
population deserving of specialist input to optimise management. 
 We propose that the establishment of a dedicated brain metastases service, 
supported by a dedicated Brain Metastases MDT, in our centre will have a positive impact on 
some of the issues highlighted in this study. This MDT was established in January 2018 and 
comprises a Neurosurgeon, Neuroradiologist, Neuro-oncologist, Palliative Care physician 
and a Brain Metastases Nurse specialist; whose role specifically includes patient education 
and support. This MDT encourages referral of all patients with brain metastases and aims to 
provide a comprehensive and individual treatment based on the patients’ wishes, with due 
consideration to their performance status and prognosis. 
 We aim to re-audit patient outcomes and treatment after a full year of the 
establishment of the MDT to ensure all patients offered SRS are discussed at our MDT, to 
assess impact of the MDT on admissions and equity of access to specialist advice, including 
improved utilisation of palliative care services by implementing an enhanced supportive care 
model in those who are identified as best supportive care at MDT. 
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Table 1-demographics 
Abbreviations: ECD = Extra cranial disease, MDT= multidisciplinary team, SACT= Systemic Anticancer 
therapy, BSC= best supportive care, WBRT= Whole Brain Radiotherapy 
*Number of local treatments exceeds patient number as some received more than one local treatment 
 
 
Abbreviations: NR=Not reached, SRS= Stereotactic Radiosurgery, WBRT= Whole Brain Radiotherapy 
SACT= Systemic Anticancer therapy, BSC=Best supportive care 
 
Table 3- Tumour specific demographics 
 Female  
 Male 
63 (51)                                 
61 (49) 
74 (66)                                
38 (34) 
 137 (58) 
99 (42) 
Age: Mean (range) 65 (30-90) 65 (33-84) 65 (30-90) 
Primary    
 Breast  
 Lung  
 Melanoma 
 Other 
23 (18) 
57 (46) 
17 (14) 
27 (22) 
25 (22) 
59 (53) 
13 (12) 
15 (13) 
48   (20) 
116 (49) 
30   (13) 
42   (18) 
ECD controlled 55 (44) 57 (51) 112 (47) 
Patients receiving local 
Therapy 
58 (47) 60 (53) 118 (50) 
 Total local 
Treatments* 
62 (49) 65 (51) 127 (100) 
 WBRT 19  (34) 30 (45) 49 (39) 
 SRS 28 (42) 23 (37) 51 (40) 
 Surgery 15 (24) 12 (18) 27 (21) 
 
SACT 12 (10) 14 (12) 26 (10) 
BSC 54 (43) 39 (35) 92 (39) 
MDT Discussion 62  (50) 63  (56) 125/236  (53) 
MDT Discussion by 
primary site 
   
 Breast  9/23  (39) 8/25     (32) 17/48       (35) 
 Lung 28/57 (49) 34/59  (58) 62/116    (53) 
 Melanoma  7/17   (41) 12/13   (92) 19/30      (63) 
 Other 18/27  (67) 9/15     (60) 27/42    (64) 
 SRS WBRT Surgery SACT BSC 
Number 51 49 27 26 92 
Median Survival NR 202 210 149 42 
Days of Follow up 16,107 11,111 7,218 4,355 5,703 
Admissions 63 80 67 33 80 
Bed Days 491 584 459 225 674 
Bed days: Follow up 3% 5.3% 6.4% 5.9% 11.8% 
      
Table 2: Treatment Related Outcome 
 Breast  
N=48 
Melanoma  
N=30 
Lung 
N=116 
Other  
N=42 
Total 
N=236 
Median Age 
(Range) 
54 years 
(30-87) 
70 years 
(33-84) 
67 years 
(38-86) 
65 years 
(40-70) 
65 years 
(30-87) 
 Male 
 Female 
1 (2%) 
47 (98%) 
18 (60%) 
12 (40%) 
57 (49%) 
59 (51%) 
23 (55%) 
19 (45%) 
99 (42%) 
137 (58%) 
Median Survival 202 days 174 days 95 days 86 days 115 days 
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Abbreviations: ECD = Extra cranial disease, SACT= Systemic Anticancer therapy, BSC= best supportive 
care, WBRT= Whole Brain Radiotherapy 
 
 
Table 4: Palliative care team contact by site 
 Breast  
N=48 
Melanoma  
N=30 
Lung 
N=116 
Other  
N=42 
Total 
N=236 
Palliative care 
contact 
 
27/48 (56%) 
 
15/30 (50%)  
 
77/116 (66%) 
 
18/42 (43%) 
 
137/236 (58%) 
 
Palliative 
contact with 
local therapy 
18/35 (51) 9/18 (50%) 28/44 (64%) 9/21 (43%) 64/118 (54%) 
Palliative 
contact  SACT  
1/2 (50%) 0/7 (0%) 3/15 (20%) 1/2 (50%) 5/26 (19%) 
Palliative care 
contact in BSC 
4/11 (36%) 1/5 (20%) 23/57 (40%) 8/19 (42%) 36/92 (39%) 
 
Abbreviations: BSC=Best supportive care, SACT= Systemic Anticancer therapy 
 
 
(Range) (5-737) (12-564) (1-829) (2-720) (1-829) 
 
ECD Control 27/48 (56%) 23/30 (77%) 37/116 (32%) 25/42 (61%) 112/236 (47%) 
MDT referral  17/48 (35%) 19/30 (63%) 61/116 (52%) 27/42 (66%) 125/236 (53%) 
Treatment:  
 SRS 
 WBRT 
 Surgery  
 SACT 
 BSC 
 
7/48 (15%) 
26/48 (54%) 
4/48   (8%) 
2/48 (4%) 
11/48 (23%) 
 
15/30 (50%) 
2/30 (6%) 
3/30 (10%) 
7/30 (23%) 
5/30 (17%) 
 
21/116 (18%) 
16/116 (14%) 
11/116 (9%) 
15/116 (13%) 
57/116 (49%) 
 
8/42 (19%) 
5/42 (12%) 
9/42 (21%) 
2/42 (5%) 
19/42 (45%) 
 
 
51/236 (22%) 
49/236 (21%) 
27/236 (11%) 
26/236 (11%) 
92/236 (39%) 
      
Admitted  36 (75%) 17 (56%) 81 (70%)  30 (71%) 164 (69%) 
Number of 
admissions 
N=61 N=34 
 
N=152 N=58 N=305 
Symptom 
 Seizure 
 Headache 
 Weakness  
 Confusion 
 Other 
 
9/61 (15%) 
15/61 (24%) 
8/61 (13%) 
11/61 18%) 
21/61 (34%)   
 
5/34 (15%) 
5/34 (15%) 
6/34 (18%) 
8/34 (23%)  
10/34 (29%) 
 
33/152 (22%)  
19/152 (12%) 
22/152 (14%) 
20/152 (13%) 
62/152 (41%) 
 
9/58 (15%) 
13/58 (22%) 
6/58 (10%) 
9/58 (15%) 
 21/58 (36%) 
 
56/305 (18%) 
52/305 (17%)  
42/305 (14%)  
48/305 (16%) 
114/305 (37%) 
Total bed days 457 216 1040 605 2318 
Median bed days 10 5 12 10 7 
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